Total Clarity Wealth Management Inc. Has $720,000 Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Total Clarity Wealth Management Inc. lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 9.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 933 shares of the company’s stock after selling 99 shares during the period. Total Clarity Wealth Management Inc.’s holdings in Eli Lilly and Company were worth $720,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in LLY. Algert Global LLC raised its holdings in Eli Lilly and Company by 27.9% in the 2nd quarter. Algert Global LLC now owns 504 shares of the company’s stock valued at $456,000 after acquiring an additional 110 shares in the last quarter. AMF Tjanstepension AB raised its holdings in Eli Lilly and Company by 113.7% in the 3rd quarter. AMF Tjanstepension AB now owns 331,786 shares of the company’s stock valued at $293,964,000 after acquiring an additional 176,552 shares in the last quarter. Czech National Bank raised its holdings in Eli Lilly and Company by 5.6% in the 3rd quarter. Czech National Bank now owns 160,697 shares of the company’s stock valued at $142,368,000 after acquiring an additional 8,566 shares in the last quarter. GAMMA Investing LLC raised its holdings in Eli Lilly and Company by 24.3% in the 3rd quarter. GAMMA Investing LLC now owns 14,491 shares of the company’s stock valued at $12,838,000 after acquiring an additional 2,833 shares in the last quarter. Finally, WealthBridge Capital Management LLC raised its holdings in Eli Lilly and Company by 55.6% in the 3rd quarter. WealthBridge Capital Management LLC now owns 5,249 shares of the company’s stock valued at $4,650,000 after acquiring an additional 1,876 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on LLY. Citigroup cut their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Bank of America reaffirmed a “buy” rating and issued a $997.00 price target on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Sanford C. Bernstein began coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price objective on the stock. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Five equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $997.22.

Eli Lilly and Company Stock Performance

LLY stock opened at $811.61 on Monday. The business’s fifty day moving average is $783.56 and its 200-day moving average is $844.18. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The company has a market cap of $770.48 billion, a P/E ratio of 87.74, a price-to-earnings-growth ratio of 1.71 and a beta of 0.41. Eli Lilly and Company has a twelve month low of $637.00 and a twelve month high of $972.53.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.74%. The ex-dividend date is Friday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Eli Lilly and Company declared that its board has initiated a share buyback program on Monday, December 9th that permits the company to buyback $15.00 billion in shares. This buyback authorization permits the company to reacquire up to 2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.